Description: UFP delivered solid Q3 results despite absorbing abnormally high costs related to the labor inefficiency challenge at our AJR Illinois facility. AJR, of 6 acquisitions we completed over the last 15 months, faced an issue when we went through the process of verifying the team's eligibility to legally work in the U.S. The e-verify process led to the turnover of greater than 50% of the direct labor workforce. July was the low point of our inefficiency when we suffered a significant loss in Illinois.

Description: Stryker (SYK) shares have been in focus recently, drawing interest from investors tracking movement in the healthcare sector. The company’s stock has seen a modest lift this week, and its long-term performance remains impressive when compared to broader market trends. See our latest analysis for Stryker. Stryker’s share price has shown a mix of short-term swings and long-term strength. The stock picked up 2.98% in the last week but is still navigating a modest pullback over the past month...

Description: The company named former Inari Medical CEO Drew Hykes as its next leader in conjunction with the financing round.

Description: The global Medical Precision Parts Market is projected to grow at a CAGR of 5.78% from 2024-2030. Driven by lab automation, precision fluidic components like micro-valves and pipetting heads advance personalized medicine. Advanced engineering boosts biocompatibility and anti-fouling, exemplified by Medtronic implants. CNC-machined parts lead with 28% market share, while metals, particularly titanium and stainless steel, drive demand in orthopedic implants. North America dominates due to advanced

Description: Knee replacement surgery effectively addresses severe knee conditions like osteoarthritis, offering pain relief and improved mobility. The procedure sees high demand due to rising osteoarthritis among the aging population, especially as global lifespans increase. Although the surgery significantly enhances life quality, challenges such as high costs and lengthy recovery persist, affecting both patients and healthcare systems. The competitive market witnesses innovation from key players like Stry

Description: Wondering if Stryker is a bargain or priced to perfection? Here is what you need to know before making your next move. Stryker’s share price recently climbed 5.5% in the last week and is up 4.1% year-to-date, though it has dipped slightly by 1.7% over the past year. Some of these moves may be tied to noteworthy partnerships and strategic acquisitions in the healthcare sector, as Stryker continues expanding its presence globally. Investors have been watching how these developments might fuel...

Description: Despite Stryker’s underperformance relative to the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Description: Intuitive Surgical's new force-feedback upgrades for da Vinci 5 could spark its next adoption wave as early clinical evidence strengthens.

Description: J&J's MedTech sales rose 5.6% in Q3, fueled by cardiovascular strength and strategic portfolio shifts toward high-growth markets.

Description: The regenerative medicine market offers significant opportunities in personalized stem cell therapies, driven by rising cancer cases and demand for effective chronic disease treatments. Emerging economies show potential for growth, propelled by an increasing need for tissue engineering and organ transplantation solutions. Regenerative Medicine Market Regenerative Medicine Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market - Global Industry Size, Share, Trends, Opp

Description: The Sports Medicine industry is projected to grow significantly, reaching US$ 12.32 Billion by 2033 from US$ 7.27 Billion in 2024, marking a CAGR of 6.04%. This growth is driven by increased sports participation, a focus on injury prevention, and advancements in sports medicine technology like minimally invasive surgical tools. Companies such as Temple Ortho Biologics are pioneering solutions for young athletes. Leading market players include Zimmer Biomet, Medtronic, and Stryker, emphasizing in

Description: Intuitive Surgical's shares soar over 28% in a month on da Vinci 5 momentum, but margin and valuation pressures suggest caution for new buyers.

Description: The market for Stryker Corporation's ( NYSE:SYK ) shares didn't move much after it posted weak earnings recently. Our...

Description: Stryker’s third quarter was marked by broad-based demand and resilient procedural volumes across its business segments, with management highlighting sustained organic sales growth and margin discipline. CEO Kevin Lobo attributed the results to strong performance in both Orthopedics and MedSurg & Neurotechnology, particularly emphasizing the impact of high Mako robotic system installations and robust growth in Trauma, Vascular, and Instruments. Lobo noted that “procedure volumes are very healthy,

Description: Stryker Corp. (SYK) reported strong financial results for the third quarter, driven by robust top-line performance. The company achieved $6.1 billion in reported sales, a significant 10.3% increase year-over-year. Net income and earnings per share also increased, highlights Ingrid Hendershot, editor of Hendershot Investments.

Description: Zimmer Biomet, the maker of knee and hip replacements, missed on quarterly sales estimates and lowered the top end of its outlook for full-year organic revenue growth.

Description: Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.

Description: While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

Description: Stryker (SYK) reported current net profit margins of 12.1%, a step down from last year’s 16.3%, with the latest results impacted by a one-off $1.4 billion loss. Notably, earnings forecasts call for annual growth of 17.3% going forward, outpacing the broader US market’s 15.9%, even as five-year annual earnings growth landed at 14.1% and turned negative in the past year. Investors have to weigh robust growth potential against recent margin compression and a demanding valuation, especially with...

Description: In the opening hour of the evening session, U.S. equity futures are notably higher, with S&P 500 up 0.5% and Nasdaq 100 contracts up 1.0%. In commodities, WTI Crude Oil is little changed just above $60 per barrel while precious metals are stronger for the 3rd day in a row – Gold is above $4,040 and Silver is approaching $49 per ounce. A strong slate of quarterly Tech results are helping stock futures restore positive sentiment in the segment that was wounded on Thursday by more dubious results o

Description: Shares of medical technology company Stryker (NYSE:SYK) fell 2.9% in the afternoon session after it reported underwhelming earnings. Stryker's revenue grew 10.2% year on year to $6.06 billion, meeting expectations, while its adjusted earnings per share of $3.19 topped consensus estimates. Despite these positive headline numbers and a slight lift in its full-year earnings guidance, investors appeared to focus on a decline in profitability. The company's operating margin contracted to 18.7% from 1

Description: The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Description: Stryker's Q3 results top estimates with double-digit sales and profit growth, but shares slip as investors weigh tariff pressures despite an upbeat 2025 outlook.

Description: Medical technology company Stryker (NYSE:SYK) met Wall Streets revenue expectations in Q3 CY2025, with sales up 10.2% year on year to $6.06 billion. Its non-GAAP profit of $3.19 per share was 1.9% above analysts’ consensus estimates.

Description: Stryker Corp (SYK) reports robust sales and EPS growth, raises full-year outlook despite facing tariff and supply chain challenges.

Description: Medical technology company Stryker (NYSE:SYK) met Wall Streets revenue expectations in Q3 CY2025, with sales up 10.2% year on year to $6.06 billion. Its non-GAAP profit of $3.19 per share was 1.9% above analysts’ consensus estimates.

Description: Stryker (SYK) delivered earnings and revenue surprises of +1.59% and +0.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Stryker raised its sales outlook for the year after third-quarter revenue rose. The medical products maker on Thursday posted a profit of $859 million, or $2.22 a share, in the quarter ended Sept. 30, compared with $834 million, or $2.16 a share, a year earlier. Stripping out certain one-time items, adjusted per-share earnings were $3.19, ahead of the $2.85 anticipated by analysts, according to FactSet.

Description: On a per-share basis, the Portage, Michigan-based company said it had net income of $2.22. Earnings, adjusted for amortization costs and costs related to mergers and acquisitions, came to $3.19 per share. The results exceeded Wall Street expectations.

Description: Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025: Third Quarter Results Reported net sales increased 10.3% to $6.1 billionOrganic net sales increased 9.5%Reported operating income margin of 18.7%Adjusted operating income margin(1) increased 90 bps to 25.6%Reported EPS increased 2.8% to $2.22Adjusted EPS(1) increased 11.1% to $3.19 Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Cur

Description: Medical technology company Stryker (NYSE:SYK) will be reporting results this Thursday afternoon. Here’s what investors should know.

Description: Beyond analysts' top-and-bottom-line estimates for Stryker (SYK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.

Description: Stryker (SYK) is in the spotlight after announcing several key expansions for its trauma device platforms at the Orthopaedic Trauma Association's annual meeting. The company's launch highlights ongoing innovation in surgical solutions. See our latest analysis for Stryker. Stryker’s rollout of new trauma device solutions comes at a time when momentum in its stock is steady, with a 6.4% year-to-date share price return reflecting solid investor confidence. Over the past year, the total...

Description: Netflix lifts its cash flow outlook, Mastercard expands via acquisitions, and Citigroup gains on strong NII and transformation progress.

Description: Stryker's Q3 results are expected to highlight MedSurg strength and solid robotics-led growth in Orthopaedics, partly offset by tariff headwinds.

Description: CAH's Pharmaceutical and Specialty units are expected to have fueled double-digit revenue growth in Q1 FY26 despite tariff and cost headwinds.

Description: Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.

Description: The GCC catheter market is projected to grow from USD 579.83 million in 2024 to USD 1.28 billion by 2033, with a CAGR of 9.21% from 2025 to 2033. This growth is driven by an increase in chronic diseases, surgical procedures, and advanced healthcare infrastructure across GCC countries. The demand for minimally invasive treatments and the aging population further bolster market expansion. Key sectors such as cardiovascular, microcatheters, and intermittent catheters are witnessing significant grow

Description: The United States Breast Reconstruction Market is projected to grow from US$ 1.02 billion in 2024 to US$ 1.74 billion by 2033, with a CAGR of 6.1% from 2025 to 2033. Key factors driving this growth include rising breast cancer incidences and an increase in breast reconstruction surgeries. The availability of insurance coverage, such as through the Women's Health and Cancer Rights Act, enhances treatment accessibility. Technological advancements like less invasive procedures and 3D-printed implan

Description: Zacks highlights three wide-moat leaders Moody's, Stryker, and CBRE poised to deliver durable returns through strong fundamentals, innovation, and strategic expansion.

Description: MCO, SYK and CBRE stand out as wide moat stocks with strong growth forecasts and strategic expansions to boost portfolio resilience.

Description: Intuitive Surgical's new da Vinci 5 is driving strong hospital upgrades and premium pricing, setting up ISRG for potential top-line momentum in Q3.

Description: Zacks highlights four GARP (Growth at a Reasonable Price) stocks Stryker, NVIDIA, ResMed, and Ralph Lauren combining strong growth prospects with attractive valuations for maximum returns.

Description: If you’ve ever wondered what to do with Stryker stock, you’re definitely not alone. This medical devices giant has long been a favorite for growth-minded investors, but its recent market moves might have you second-guessing. After a small dip last month, Stryker’s share price has started to gain some traction again, up 2.7% in just the last week. Year to date, it’s notched a 4.4% return, and over the past three years, investors have seen a remarkable 76.7% gain. While the pace has slowed in...

Description: Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. SYK, NVDA, RMD and RL hold promise.

Description: Stryker will release its third-quarter earnings later this month, and analysts anticipate a high single-digit bottom-line growth.